Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics, Inc. (CVKD) reported that stockholders approved an amendment increasing shares available for awards under the 2022 Successor Equity Incentive Plan by 323,542 shares to 1,000,000 shares. They also approved issuance of up to 960,000 common shares upon exercise of Series C-1 warrants issued in a private placement that closed July 1, 2026.
Quang X. Pham was elected a Class I director to serve until the 2029 annual meeting, and stockholders ratified WithumSmith+Brown, P.C. as the independent registered public accounting firm for fiscal 2026. Although an adjournment proposal passed, the meeting did not need to adjourn because the plan amendment and warrant proposals received the votes required for approval. As of July 27, 2026, 3,567,592 common shares were outstanding and entitled to vote; 2,155,341 shares were represented at the meeting.
Cadrenal Therapeutics, Inc. (CVKD) reported that the FDA provided positive feedback in a Type D Meeting held on July 28, 2026, aligning with the company on key elements of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT).
The FDA agreed to an optimized definition of worsening HIT for the composite primary endpoint, focusing on progression of thrombotic events or hospital discharge through Day 14, including extension of existing thrombi into new vascular segments. The agency also agreed to a placebo-controlled design, with both CAD-1005 and placebo arms receiving standard anticoagulation, and to assess bleeding using International Society on Thrombosis and Haemostasis criteria. Cadrenal highlights HIT as a ~50,000 patient acute market in the U.S. and cites a projected $2 billion peak annual revenue opportunity for CAD-1005.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, tecarfarin and frunexian for critical care cardiology and orphan cardiovascular conditions. For the six months ended June 30, 2026, it reported a net loss of $5.8 million, an improvement from $7.5 million a year earlier, as total operating expenses fell 24% to $5.9 million. Cash used in operations was $5.2 million.
At June 30, 2026, Cadrenal held $2.4 million in cash and cash equivalents, total assets of $5.6 million and stockholders’ equity of $4.1 million, with an accumulated deficit of $44.8 million. Management states that expected operating losses and capital needs will exceed existing cash, raising substantial doubt about its ability to continue as a going concern without additional financing. The company raised capital through an April 2026 warrant exercise and a June 2026 PIPE and is pursuing further equity, debt, grants and partnerships while prioritizing early- to mid-stage validation and out-licensing rather than self-funding Phase 3 trials.
Cadrenal Therapeutics, Inc. reported second quarter 2026 results and outlined progress in its Cardiac Acute Critical Care Franchise and strategic partnering efforts. For the quarter ended June 30, 2026, the company recorded a net loss of $3.3 million on total operating expenses of $3.3 million, both slightly improved versus 2025.
For the six months ended June 30, 2026, total operating expenses were $5.9 million compared with $7.7 million a year earlier, and the net loss narrowed to $5.8 million from $7.5 million, reflecting lower research and development spending. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents and expects its resources to fund operations through the first quarter of 2027.
The company states that existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to commence and complete clinical trials and that it does not plan to start a trial unless funding sufficient to complete that trial is secured, potentially via partnerships, out-licensing, grants, or financings.
Cadrenal Therapeutics, Inc. reports that The PNC Financial Services Group, Inc., through its subsidiary PNC Bank, National Association, holds a beneficial position in the company’s common stock.
PNC reports beneficial ownership of 233,219 shares of Cadrenal common stock, representing 8.13% of the class as of June 30, 2026. PNC has sole voting and dispositive power over these shares, with no shared voting or dispositive power. The shares are held in a fiduciary account at PNC Bank for a client, identified as Daniel Maltz, who has the right to receive dividends and sale proceeds from this more-than-5% position.
Cadrenal Therapeutics, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on several governance and capital proposals.
Items include electing one Class I director, ratifying WithumSmith+Brown, PC as auditor for 2026, and amending the 2022 Successor Equity Incentive Plan to add 323,542 shares, bringing the plan reserve to 1,000,000 shares. Stockholders are also asked to approve, under Nasdaq Rule 5635(d), the potential issuance of up to 960,000 shares upon exercise of Series C-1 warrants issued in a July 1, 2026 private placement, and to permit adjournment if more time is needed to solicit votes on the equity plan or warrant proposals. There were 3,567,592 shares of common stock outstanding and entitled to vote as of July 27, 2026, and the board recommends voting FOR all proposals.
Cadrenal Therapeutics, Inc. is calling a virtual annual stockholder meeting on September 24, 2026. Stockholders of record as of July 27, 2026 will vote on five proposals.
The agenda includes electing Quang X. Pham, the current Chairman and CEO, as the sole Class I director for a term running to the 2029 annual meeting, and ratifying WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026. Stockholders are also asked to approve an amendment to the 2022 Successor Equity Incentive Plan to increase shares available for awards by 323,542 shares, bringing the plan’s share reserve to 1,000,000 shares. Another proposal seeks approval under Nasdaq Rule 5635(d) for the potential issuance of up to 960,000 shares of common stock upon exercise of Series C‑1 warrants issued in a July 1, 2026 private placement. A further proposal would permit adjournment of the meeting to solicit additional proxies if needed for the equity plan or warrant proposals.
The board has four members, three of whom are deemed independent, and recommends a FOR vote on all proposals. The filing also details board committee structures, director compensation for 2025, and audit fees of $157,050 for 2025.
Cadrenal Therapeutics, Inc. reoriented its pipeline by creating a unified Cardiac Acute Critical Care Franchise and starting a structured process to pursue strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets.
The company highlighted late-breaking Phase 2 data for CAD-1005 presented at the ISTH 2026 Congress, showing a greater than 25% absolute reduction in thrombotic events with a favorable safety and renal-protective baseline. CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia, has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA. The franchise also includes frunexian, an IV Factor XIa inhibitor, and tecarfarin, an oral vitamin K antagonist being advanced for chronic anticoagulation indications and rare pediatric disease protocols that the company states could potentially qualify for a Priority Review Voucher. Beyond the franchise, Cadrenal is progressing CAD-2000, an oral 12-LOX inhibitor for chronic cardiorenal inflammatory and thrombotic indications, as a companion to its IV acute care platform.